New asthma drug aims to slash severe attacks in eosinophilic patients
NCT ID NCT06653322
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new medicine called SHR-1703 to see if it can reduce asthma attacks in people with eosinophilic asthma, a type of asthma linked to high levels of certain white blood cells. About 400 participants aged 12 and older who already use daily inhaled steroids and other asthma controllers will receive either SHR-1703 or a placebo. The main goal is to track how many asthma attacks occur over about 48 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA WITH EOSINOPHILIC PHENOTYPE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China School of Medicine West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.